Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
Natera (NASDAQ: NTRA), a leading provider of cell-free DNA and genetic testing services, has announced its upcoming fourth quarter and full year 2024 financial results release. The company will disclose its results after market close on February 27, 2025, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).
Interested parties can access the conference call through domestic (1-888-770-7321) or international (1-929-201-7101) dial-in numbers using Conference ID 7684785. A webcast will be available at the provided link, with a replay accessible later at investor.natera.com.
Natera (NASDAQ: NTRA), un fornitore leader di servizi di test genetici e di DNA libero, ha annunciato il rilascio dei risultati finanziari del quarto trimestre e dell'intero anno 2024. L'azienda divulgherà i suoi risultati dopo la chiusura del mercato il 27 febbraio 2025, seguito da una conference call e webcast alle 13:30 PT (16:30 ET).
Le parti interessate possono accedere alla conference call tramite i numeri di telefono nazionali (1-888-770-7321) o internazionali (1-929-201-7101) utilizzando l'ID Conferenza 7684785. Un webcast sarà disponibile al link fornito, con una registrazione accessibile in seguito su investor.natera.com.
Natera (NASDAQ: NTRA), un proveedor líder de servicios de pruebas genéticas y de ADN libre, ha anunciado la próxima publicación de sus resultados financieros del cuarto trimestre y del año completo 2024. La compañía revelará sus resultados después del cierre del mercado el 27 de febrero de 2025, seguido de una llamada de conferencia y un webcast a las 1:30 p.m. PT (4:30 p.m. ET).
Las partes interesadas pueden acceder a la llamada de conferencia a través de números de marcado nacionales (1-888-770-7321) o internacionales (1-929-201-7101) utilizando el ID de Conferencia 7684785. Un webcast estará disponible en el enlace proporcionado, con una repetición accesible más tarde en investor.natera.com.
Natera (NASDAQ: NTRA), 세포 자유 DNA 및 유전자 검사 서비스의 선도적인 제공업체가 2024년 4분기 및 전체 연도 재무 결과 발표를 예고했습니다. 회사는 2025년 2월 27일 시장 종료 후 결과를 공개하며, 오후 1:30 PT (오후 4:30 ET)에 컨퍼런스 콜 및 웹캐스트가 이어질 예정입니다.
관심 있는 분들은 국내 전화번호(1-888-770-7321) 또는 국제 전화번호(1-929-201-7101)를 통해 컨퍼런스 콜에 접속할 수 있으며, 회의 ID 7684785를 사용해야 합니다. 제공된 링크에서 웹캐스트를 이용할 수 있으며, 나중에 investor.natera.com에서 재생할 수 있습니다.
Natera (NASDAQ: NTRA), un fournisseur leader de services de tests génétiques et d'ADN libre, a annoncé la prochaine publication de ses résultats financiers pour le quatrième trimestre et l'année entière 2024. La société divulguera ses résultats après la fermeture du marché le 27 février 2025, suivie d'une conférence téléphonique et d'un webinaire à 13h30 PT (16h30 ET).
Les parties intéressées peuvent accéder à la conférence téléphonique via des numéros de composition nationaux (1-888-770-7321) ou internationaux (1-929-201-7101) en utilisant l'ID de conférence 7684785. Un webinaire sera disponible via le lien fourni, avec une rediffusion accessible ultérieurement sur investor.natera.com.
Natera (NASDAQ: NTRA), ein führender Anbieter von zellfreier DNA und genetischen Testdiensten, hat die bevorstehende Veröffentlichung seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 angekündigt. Das Unternehmen wird seine Ergebnisse nach Marktschluss am 27. Februar 2025 bekannt geben, gefolgt von einer Telefonkonferenz und einem Webcast um 13:30 Uhr PT (16:30 Uhr ET).
Interessierte Parteien können über die nationalen (1-888-770-7321) oder internationalen (1-929-201-7101) Telefonnummern auf die Telefonkonferenz zugreifen, indem sie die Konferenz-ID 7684785 verwenden. Ein Webcast wird unter dem angegebenen Link verfügbar sein, mit einer späteren Wiederholung, die unter investor.natera.com zugänglich ist.
- None.
- None.
Earnings Conference Call Information
Event: |
Natera’s Fourth Quarter & Full Year 2024 Financial Results |
|
Date: |
February 27, 2025 |
|
Time: |
1:30 p.m. PT (4:30 p.m. ET) |
|
Live Dial-In: |
1-888-770-7321 (Domestic) |
|
1-929-201-7101 (International) |
||
Conference ID: |
7684785 |
|
Webcast: |
A webcast replay will be available at investor.natera.com.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218525659/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
When will Natera (NTRA) release its Q4 and full-year 2024 earnings?
What time is Natera's (NTRA) Q4 2024 earnings call?
How can investors join Natera's (NTRA) Q4 2024 earnings call?
Where can I find the replay of Natera's (NTRA) Q4 2024 earnings call?
